iBio
NASDAQ: IBIOSan Diego, US · Delaware corporation
iBio discovers antibody-based medicines for obesity and cardiometabolic disease, using an AI-assisted platform to design antibodies against hard-to-drug targets. The company operates in the biotech and drug discovery space.
AI & Machine LearningBiotechLongevity
Founders & leadership
FD
Felipe DuraninExecutive
MB
Marc BanjakinExecutive
MA
Martin A. BrennerExecutive
TR
Terence RyanChief Scientific Officer
RK
Robert KayExecutive Chairman and Chief Executive Officer
MG
Mark GiannoneChief Financial Officer
RE
Robert ErwinPresident
Board
AK
Alexandra KroptovaBoard director
GS
Gary SenderBoard director
DA
David ArkowitzBoard director
WC
William ClarkBoard director
AP
Antonio ParadaBoard director
Reported raises · per SEC filings
Form D private placements$54.3M disclosed across 4 of 5 rounds · 2016–2026
▶$26MraisedJan 2026 · 7 investors · BiotechnologyRule 506(b)
▶$26MraisedJan 2026 · 7 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- David ArkowitzDirector
- William ClarkDirector
- Martin A. BrennerExecutive Officer, Director
- Antonio ParadaDirector
- Marc BanjakExecutive Officer
- Evert ShimmelpenninkDirector
- Felipe DuranExecutive Officer
- Alexandra KropotovaDirector
- Gary SenderDirector
- Offering amount
- $26M
- Amount sold
- $26M
- Sales commissions
- $1.6M
- Placement agents
- Oppenheimer & Co. Inc., LifeSci Capital LLC, Leerink Partners LLC
- First sale
- Jan 2026
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$11.1MraisedMay 2025 · 5 investors · BiotechnologyRule 506(b)
▶$11.1MraisedMay 2025 · 5 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Felipe DuranExecutive Officer
- Marc BanjakExecutive Officer
- Alexandra KroptovaDirector
- Gary SenderDirector
- David ArkowitzDirector
- Martin A. BrennerExecutive Officer, Director
- William ClarkDirector
- Antonio ParadaDirector
- Evert ShimmelpenninkDirector
- Offering amount
- $11.1M
- Amount sold
- $11.1M
- Sales commissions
- $217K
- Placement agents
- Chardan Capital Markets LLC
- First sale
- Apr 2025
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$15.1MraisedApr 2024 · 8 investors · BiotechnologyRule 506(b)
▶$15.1MraisedApr 2024 · 8 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Felipe DuranExecutive Officer
- Gary SendeDirector
- William ClarkDirector
- Martin BrennerExecutive Officer
- Linda ArmstrongDirector
- James HillDirector
- Evert ShimmelpenninkDirector
- Alexandra KropotovaDirector
- Offering amount
- $15.1M
- Amount sold
- $15.1M
- Sales commissions
- $794.1K
- Placement agents
- Chardan Capital Markets LLC
- First sale
- Mar 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$10MofferedAug 2023 · 1 investors · BiotechnologyRule 506(b)
▶$10MofferedAug 2023 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Marc BanjakExecutive Officer
- Gary SenderDirector
- Martin BrennerExecutive Officer
- Linda ArmstrongDirector
- James HillDirector
- Alexandra KropotovaDirector
- Evert SchimmelpenninkDirector
- William ClarkDirector
- Felipe DuranExecutive Officer
- Offering amount
- $10M
- First sale
- Aug 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$2.2MraisedFeb 2016 · 1 investors · BiotechnologyRule 506(b)
▶$2.2MraisedFeb 2016 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Terence RyanExecutive Officer
- Robert KayExecutive Officer
- Mark GiannoneExecutive Officer
- Arthur ElliottDirector
- Glenn ChangDirector
- James HillDirector
- Philip RussellDirector
- John McKeyDirector
- Robert ErwinExecutive Officer
- Seymour FlugDirector
- Offering amount
- $2.2M
- Amount sold
- $2.2M
- First sale
- Jan 2016
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 4
by search overlap
Robinhood65 shared keywordsRobinhood is a financial trading platform that enables users to manage portfolios across stocks, ETFs, cryptocurrencies, options, futures, and prediction markets. The platform serves retail investors with low barriers to entry, offering portfolio management services and market insights.
Seeking Alpha60 shared keywordsSeeking Alpha is a financial research platform that provides stock analysis, investment tools, and market coverage across asset classes to investors. The platform aggregates research from thousands of analysts and investors, offering ratings, articles, and investment ideas.
bio51 shared keywordsThe Biotechnology Innovation Organization (BIO) is an advocacy organization representing biotech companies, industry leaders, and state biotech associations across the United States and more than 35 countries. It provides members with policy advocacy, cost-saving programs, educational webinars, and organizes the BIO International Convention and other industry conferences.
IO Biotech47 shared keywordsThe page presents a biography of Dr. Dhingra, a medical oncologist and physician-scientist with experience in oncology drug development. It provides no clear description of the company's own products or services.
Companies competing with iBio for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does iBio do?
- iBio discovers antibody-based medicines for obesity and cardiometabolic disease, using an AI-assisted platform to design antibodies against hard-to-drug targets. The company operates in the biotech and drug discovery space.
- How much funding has iBio raised?
- iBio has disclosed $54.3M raised across 4 of its 5 known rounds.
- Where is iBio headquartered?
- iBio is headquartered in San Diego, US.